165 related articles for article (PubMed ID: 19362972)
1. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
Kastritis E; Zervas K; Repoussis P; Michali E; Katodrytou E; Zomas A; Simeonidis A; Terpos E; Delimbassi S; Vassou A; Gika D; Dimopoulos MA;
Clin Lymphoma Myeloma; 2009 Mar; 9(1):50-2. PubMed ID: 19362972
[TBL] [Abstract][Full Text] [Related]
2. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH).
Kastritis E; Kyrtsonis MC; Hadjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas C; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA;
Leuk Res; 2010 Oct; 34(10):1340-3. PubMed ID: 20447689
[TBL] [Abstract][Full Text] [Related]
3. Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Kyrtsonis MC; Vassilakopoulos TP; Angelopoulou MK; Siakantaris P; Kontopidou FN; Dimopoulou MN; Boussiotis V; Gribabis A; Konstantopoulos K; Vaiopoulos GA; Fessas P; Kittas C; Pangalis GA
Ann Hematol; 2001 Dec; 80(12):722-7. PubMed ID: 11797112
[TBL] [Abstract][Full Text] [Related]
4. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
Ghobrial IM; Fonseca R; Gertz MA; Plevak MF; Larson DR; Therneau TM; Wolf RC; Hoffmann RJ; Lust JA; Witzig TE; Lacy MQ; Dispenzieri A; Vincent Rajkumar S; Zeldenrust SR; Greipp PR; Kyle RA
Br J Haematol; 2006 Apr; 133(2):158-64. PubMed ID: 16611306
[TBL] [Abstract][Full Text] [Related]
5. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: a two-institution study.
Björkholm M; Johansson E; Papamichael D; Celsing F; Matthews J; Lister TA; Rohatiner AZ
Semin Oncol; 2003 Apr; 30(2):226-30. PubMed ID: 12720141
[TBL] [Abstract][Full Text] [Related]
6. The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis.
Ricci F; Tedeschi A; Vismara E; Greco A; Montillo M; Nichelatti M; Varettoni M; Lazzarino M; Morra E
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):124-6. PubMed ID: 21454211
[TBL] [Abstract][Full Text] [Related]
7. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L; Goldaniga M; Guffanti A; Broglia C; Cortelazzo S; Rossi A; Morra E; Colombi M; Callea V; Pogliani E; Ilariucci F; Luminari S; Morel P; Merlini G; Gobbi P
J Clin Oncol; 2005 Jul; 23(21):4662-8. PubMed ID: 16034042
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
[TBL] [Abstract][Full Text] [Related]
10. No significant improvement in the outcome of patients with Waldenström's macroglobulinemia treated over the last 25 years.
Kastritis E; Kyrtsonis MC; Hatjiharissi E; Symeonidis A; Michalis E; Repoussis P; Tsatalas K; Michael M; Sioni A; Kartasis Z; Stefanoudaki E; Voulgarelis M; Delimpasi S; Gavriatopoulou M; Koulieris E; Gika D; Vervesou E; Konstantopoulos K; Kokkini G; Zomas A; Roussou P; Anagnostopoulos N; Economopoulos T; Terpos E; Zervas K; Dimopoulos MA
Am J Hematol; 2011 Jun; 86(6):479-83. PubMed ID: 21509798
[TBL] [Abstract][Full Text] [Related]
11. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.
Terpos E; Katodritou E; Roussou M; Pouli A; Michalis E; Delimpasi S; Parcharidou A; Kartasis Z; Zomas A; Symeonidis A; Viniou NA; Anagnostopoulos N; Economopoulos T; Zervas K; Dimopoulos MA;
Eur J Haematol; 2010 Aug; 85(2):114-9. PubMed ID: 20477863
[TBL] [Abstract][Full Text] [Related]
12. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
Lévy V; Morel P; Porcher R; Chevret S; Wattel E; Leblond V
Haematologica; 2005 Feb; 90(2):279-81. PubMed ID: 15710594
[TBL] [Abstract][Full Text] [Related]
13. Excellent long-term survival of 170 patients with Waldenström's macroglobulinemia treated in private oncology practices and a university hospital.
Hensel M; Brust J; Plöger C; Schuster D; Memmer ML; Franz-Werner J; Feustel HP; Karcher A; Fuxius S; Mosthaf FA; Rieger M; Ho AD; Witzens-Harig M
Ann Hematol; 2012 Dec; 91(12):1923-8. PubMed ID: 22895554
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
Vidulich KA; Talpur R; Bassett RL; Duvic M
Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
[TBL] [Abstract][Full Text] [Related]
15. Prognosis and treatment of Waldenström's macroglobulinemia.
Louw VJ; Webb MJ
Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
[TBL] [Abstract][Full Text] [Related]
16. Multiple myeloma in elderly patients: prognostic factors and outcome.
Anagnostopoulos A; Gika D; Symeonidis A; Zervas K; Pouli A; Repoussis P; Grigoraki V; Anagnostopoulos N; Economopoulos T; Maniatis A; Dimopoulos MA
Eur J Haematol; 2005 Nov; 75(5):370-5. PubMed ID: 16191085
[TBL] [Abstract][Full Text] [Related]
17. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia.
Vitolo U; Ferreri AJ; Montoto S
Crit Rev Oncol Hematol; 2008 Aug; 67(2):172-85. PubMed ID: 18499469
[TBL] [Abstract][Full Text] [Related]
18. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.
Stalnikiewicz L; Carrotte-Lefebvre I; Detourmignies L; Rose C; Cazin B; Leblond V; Morel P
Semin Oncol; 2003 Apr; 30(2):216-9. PubMed ID: 12720139
[TBL] [Abstract][Full Text] [Related]
20. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
